Zomedica Corp
Change company Symbol lookup
Select an option...
ZOM Zomedica Corp
C Citigroup Inc
WMT WALMART STORES INC
AMANX Amana Mutual Funds Trust Income Fund Investor
BAC Bank of America Corp
GMS GMS Inc
$VX3MN.X CBOE Near-Term VIX3M
TSHA Taysha Gene Therapies Inc
PTPI Petros Pharmaceuticals Inc
MGDPF Marathon Gold Corp
Go

Health Care : Pharmaceuticals | Small Cap Growth
Company profile

Zomedica Corp., formerly Zomedica Pharmaceuticals Corp., is a development stage veterinary diagnostic and pharmaceutical company. The Company is engaged in developing products for companion animals, such as canine, feline, and equine by focusing on needs of clinical veterinarians. It is focused on developing three diagnostic platforms, a Bulk Acoustic Wave sensor-based veterinary point-of-care diagnostic platform for performing immunodiagnostic testing, a Raman spectroscopy-based point-of-care diagnostic platform for the detection of pathogens, and liquid biopsy assays for the detection of cancer, along with related consumables. The Company’s TRUFORMA product candidate is an investigational device being developed as a point-of-care biosensor platform. ZM-020 is its diagnostic platform being developed to screen for a range of pathogens in companion animal feces, urine, respiratory, and dermatological samples. It is developing ZM-017 as a canine cancer liquid biopsy platform.

Closing Price
$0.85
Day's Change
-0.1251 (-12.83%)
Bid
--
Ask
--
B/A Size
--
Day's High
0.9405
Day's Low
0.83
Volume
(Average)
Volume:
80,755,756

10-day average volume:
83,833,990
80,755,756

Company Profile

Zomedica Corp., formerly Zomedica Pharmaceuticals Corp., is a development stage veterinary diagnostic and pharmaceutical company. The Company is engaged in developing products for companion animals, such as canine, feline, and equine by focusing on needs of clinical veterinarians. It is focused on developing three diagnostic platforms, a Bulk Acoustic Wave sensor-based veterinary point-of-care diagnostic platform for performing immunodiagnostic testing, a Raman spectroscopy-based point-of-care diagnostic platform for the detection of pathogens, and liquid biopsy assays for the detection of cancer, along with related consumables. The Company’s TRUFORMA product candidate is an investigational device being developed as a point-of-care biosensor platform. ZM-020 is its diagnostic platform being developed to screen for a range of pathogens in companion animal feces, urine, respiratory, and dermatological samples. It is developing ZM-017 as a canine cancer liquid biopsy platform.

Valuation Ratios

Price/Earnings (TTM)
--
Price/Sales (TTM)
--
Price/Book (MRQ)
10.69x
Price/Cash Flow (TTM)
--
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

No historic growth available.

Short Interest

March 2021
Current Month
51.3M
Previous Month
59.6M
Percent of Float
5.56%
Days to Cover
0.6408 Days

Share Information

ZOM is in a share class of common stock
Float
908.3M
Shares Outstanding
947.3M
Institutions Holding Shares
44
7.27%

Financial Statements

Balance sheet

Values displayed are in thousands.

Income statement

Values displayed are in thousands.

Cash flow

Values displayed are in thousands.

Company Officers

  • Jeffrey Mark RoweChmn.
  • Stephanie Laine MorleyPres.
  • Robert CohenCEO
  • Ann CotterCFO
  • William Carpenter MacArthurEDR

Address

Insider Trading

During the most recent quarter, 2M shares were sold in insider trading.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2021. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.